The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection

被引:5
作者
Crum-Cianflone, Nancy F. [1 ,2 ]
Roediger, Mollie [2 ,3 ]
Hullsiek, Kathy Huppler [2 ,3 ]
Ganesan, Anuradha [2 ,4 ]
Landrum, Michael [2 ,5 ]
Weintrob, Amy [2 ,6 ]
Agan, Brian [2 ]
Medina, Sheila [2 ]
Rahkola, Jeremy [7 ,9 ]
Hale, Braden [2 ,8 ]
Janoff, Edward N. [7 ,9 ]
机构
[1] USN, San Diego Med Ctr, Clin Invest Dept KCA, San Diego, CA 92134 USA
[2] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA
[3] Univ Minnesota, Div Biostat, Minneapolis, MN USA
[4] Natl Naval Med Ctr, Bethesda, MD USA
[5] San Antonio Mil Med Ctr, San Antonio, TX USA
[6] Walter Reed Army Med Ctr, Washington, DC 20307 USA
[7] Univ Colorado, Mucosal & Vaccine Res Program Colorado MAVRC, Denver, CO 80202 USA
[8] USN, Hlth Res Ctr, San Diego, CA 92134 USA
[9] Denver Vet Affairs Med Ctr, Denver, CO USA
基金
美国国家卫生研究院;
关键词
Ethnicity; Antibodies; Pneumococcal vaccination; HIV; IMMUNODEFICIENCY-VIRUS-INFECTION; HIV-1-INFECTED UGANDAN ADULTS; POLYSACCHARIDE VACCINE; RISK-FACTORS; RESISTANCE PATTERNS; CLINICAL-FEATURES; CHARLESTON COUNTY; CONJUGATE VACCINE; SOUTH-CAROLINA; DISEASE;
D O I
10.1016/j.vaccine.2010.09.056
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ethnicity may be associated with the incidence of pneumococcal infections and the frequency of protective vaccine responses. Earlier studies have suggested that HIV-infected persons of black ethnicity develop less robust immune responses to pneumococcal vaccination that may relate to their higher incidence of invasive disease. We evaluated the association of ethnicity with capsule-specific antibody responses to pneumococcal revaccination, with either the pneumococcal conjugate (PCV) or polysaccharide (PPV) vaccines among 188 HIV-infected adults. The proportion of the 77 African Americans (AA) and 111 Caucasians with comparable virologic and immunologic parameters who achieved a positive immune response (>= 2-fold rise in capsule-specific IgG from baseline with post-vaccination value >= 1 mu g/mL for >= 2 of 4 serotypes) at day 60 after revaccination was similar (43% vs. 49%, respectively, p = 0.65). Results were also similar when vaccine types (PPV and PCV) were examined separately. Mean changes in log(10) transformed IgG levels from baseline to days 60 and 180 post-vaccination were also not significantly different between AA and Caucasians. In summary, in this ethnically diverse cohort with equal access to care, we did not observe differential antibody responses between AA and Caucasian HIV-infected adults after pneumococcal revaccination. Published by Elsevier Ltd.
引用
收藏
页码:7583 / 7588
页数:6
相关论文
共 27 条
[1]   Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003 [J].
Barry, PM ;
Zetola, N ;
Keruly, JC ;
Moore, RD ;
Gebo, KA ;
Lucas, GM .
AIDS, 2006, 20 (03) :437-444
[2]   PNEUMOCOCCAL BACTEREMIA IN MONROE COUNTY, NEW-YORK [J].
BENNETT, NM ;
BUFFINGTON, J ;
LAFORCE, FM .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1992, 82 (11) :1513-1516
[3]   Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients [J].
Breiman, RF ;
Keller, DW ;
Phelan, MA ;
Sniadack, DH ;
Stephens, DS ;
Rimland, D ;
Farley, MM ;
Schuchat, A ;
Reingold, AL .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (17) :2633-2638
[4]   PNEUMOCOCCAL BACTEREMIA IN CHARLESTON COUNTY, SOUTH-CAROLINA - A DECADE LATER [J].
BREIMAN, RF ;
SPIKA, JS ;
NAVARRO, VJ ;
DARDEN, PM ;
DARBY, CP .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (07) :1401-1405
[5]   Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion [J].
Brodine, SK ;
Shaffer, RA ;
Starkey, MJ ;
Tasker, SA ;
Gilcrest, JL ;
Louder, MK ;
Barile, A ;
VanCott, TC ;
Vahey, MT ;
McCutchan, FE ;
Birx, DL ;
Richman, DD ;
Mascola, JR .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (07) :502-+
[6]   ANTIBODY CLASS AND SUBCLASS RESPONSES TO PNEUMOCOCCAL POLYSACCHARIDES FOLLOWING IMMUNIZATION OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS [J].
CARSON, PJ ;
SCHUT, RL ;
SIMPSON, ML ;
OBRIEN, J ;
JANOFF, EN .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (02) :340-345
[7]  
Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1
[8]   Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay [J].
Concepcion, NF ;
Frasch, CE .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2001, 8 (02) :266-272
[9]   A Randomized Clinical Trial Comparing Revaccination with Pneumococcal Conjugate Vaccine to Polysaccharide Vaccine among HIV-Infected Adults [J].
Crum-Cianflone, Nancy F. ;
Hullsiek, Katherine Huppler ;
Roediger, Mollie ;
Ganesan, Anuradha ;
Patel, Sugat ;
Landrum, Michael L. ;
Weintrob, Amy ;
Agan, Brian K. ;
Medina, Sheila ;
Rahkola, Jeremy ;
Hale, Braden R. ;
Janoff, Edward N. .
JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (07) :1114-1125
[10]   Pneumococcal disease among human immunodeficiency virus-infected persons: Incidence, risk factors, and impact of vaccination [J].
Dworkin, MS ;
Ward, JW ;
Hanson, DL ;
Jones, JL ;
Kaplan, JE .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (05) :794-800